RP-6306: a first-in-class, orally available and selective PKMYT1 inhibitor for the treatment of CCNE1-amplified tumors
Sep. 12, 2022
The PKMYT1 kinase has emerged as a promising therapeutic target for CCNE1-amplified cancers, after a recently reported genome-scale CRISPR/Cas9-based screen identified its inhibition as synthetically lethal for CCNE1 amplification.
